PD 0332991-d8 – 500 µg

Brand:
Cayman
CAS:
1628752-83-9
Storage:
-20
UN-No:
Non-Hazardous - /

PD 0332991-d8 is intended for use as an internal standard for the quantification of PD 0332991 (Item No. 16273) by GC- or LC-MS. PD 0332991 is an orally active, selective inhibitor of the cyclin D kinases Cdk4 (IC50 = 11 nM) and Cdk6 (IC50= 16 nM) with no activity against a panel of 36 additional protein kinases.{28137} It has been reported to have antiproliferative activity against retinoblastoma-positive tumor cells, blocking retinoblastoma phosphorylation and inducing G1 arrest at nanomolar concentrations. PD 0332991 can inhibit the growth of certain ER-positive or HER2-amplified breast cancer cells (IC50s as low as 4 nM) and demonstrates synergy with tamoxifen (Item No. 13258) and trastuzumab, respectively.{28138} PD 0332991 inhibition of Cdk4 activity has been used to demonstrate a role for insulin-activated cyclin D1-Cdk4 signaling in the control of glucose metabolism that is independent of cell cycle progression.{26552}  

 

Available on backorder

SKU: 25421 - 500 µg Category:

Description

An internal standard for the quantification of PD 0332991 by GC- or LC-MS


Formal name: 6-acetyl-8-cyclopentyl-5-methyl-2-[[5-(1-piperazinyl-2,2,3,3,5,5,6,6-d8)-2-pyridinyl]amino]-pyrido[2,3-d]pyrimidin-7(8H)-one

Synonyms:  Palbociclib-d8

Molecular weight: 455.6

CAS: 1628752-83-9

Purity: ≥99% deuterated forms (d1-d8)

Formulation: A solid


Application|Mass Spectrometry||Product Type|Biochemicals|Analytical Standards||Product Type|Biochemicals|Isotopically Labeled Standards|Deuterium||Product Type|Biochemicals|Kinase Inhibitors|CDKs||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Cycle||Research Area|Cancer|Cell Signaling||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes